07.13.10
A novel saw palmetto extract (SPE), SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH), according to a study published in the July issue of Advances in Therapy.
The study, sponsored by Euromed, makers of SPET-085, evaluated the in vitro potency of SPET-085, an inhibitor of the 5α-reductase isoenzyme type II, in a cell-free test system. It revealed that SPET-085 can effectively inhibit the enzyme linked to BPH, at a lower dose as compared to hexane extracts of saw palmetto, currently regarded as the most clinically effective saw palmetto, but unavailable in the U.S.
Importantly, the study revealed that SPET-085 has bioactivity similar to finasteride, the most commonly prescribed prescription medicine for the treatment of BPH. Common finasteride side effects may include decreased sex drive, impotence or decreased ejaculate amount. For further information www.euromedusa.com
The study, sponsored by Euromed, makers of SPET-085, evaluated the in vitro potency of SPET-085, an inhibitor of the 5α-reductase isoenzyme type II, in a cell-free test system. It revealed that SPET-085 can effectively inhibit the enzyme linked to BPH, at a lower dose as compared to hexane extracts of saw palmetto, currently regarded as the most clinically effective saw palmetto, but unavailable in the U.S.
Importantly, the study revealed that SPET-085 has bioactivity similar to finasteride, the most commonly prescribed prescription medicine for the treatment of BPH. Common finasteride side effects may include decreased sex drive, impotence or decreased ejaculate amount. For further information www.euromedusa.com
